BCD-131 is a pegylated darbepoetin beta (international nonproprietary name: pegdarbepoetin beta) whose mechanism of action is to stimulate erythropoiesis¹ by interacting with erythropoietin receptors² on progenitor cells in the bone marrow.

BCD-131 is one of BIOCAD’s drug products under clinical development.

Erythrocytes are red blood cells that carry oxygen.

Erythropoietin receptors are special proteins that interact with the kidney hormone erythropoietin, whose levels decrease in chronic kidney disease³.

Borodulin V.B., Bychkov E.N., Protopopov A.A., Rebrov A.P., Shevchenko O.V., Nesterenko O.V., Kiselev A.R., Bobyleva E.V. Scientific Journal"Basic Research". Issue #11 (part 1). 2013. pp. 22-26. URL: https://fundamental-research.ru/ru/article/view?id=33003​

This website section includes information about an investigational medicinal product for human use.